Literature DB >> 11445798

Long-term clinical outcome in patients with glutathione synthetase deficiency.

E Ristoff1, E Mayatepek, A Larsson.   

Abstract

OBJECTIVE: The objective was to determine the long-term clinical outcome and the effects of treatment of patients with glutathione synthetase (GS) deficiency (n = 28).
METHODS: The diagnosis was based on demonstration of a marked decrease in GS activity in erythrocytes or cultured fibroblasts in all patients and was supported by finding a decrease in erythrocyte or fibroblast glutathione, presence of 5-oxoprolinuria, or both. The treatment varied but usually included correction of acidosis and supplementation with vitamins C and/or E.
RESULTS: Sixteen patients were severely affected with neurologic symptoms such as seizures and psychomotor retardation; 7 had died at the time of the study. None of the severely affected patients had been treated with both vitamins C and E from the neonatal period. No significant difference was found in GS activity between patients with or without neurologic symptoms or in erythrocyte or fibroblast glutathione levels. Five patients had recurrent bacterial infections.
CONCLUSION: On the basis of clinical symptoms, patients with GS deficiency can be classified into 3 phenotypes: mild, moderate, and severe. Our results indicate that early supplementation with vitamins C and E may improve the long-term clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445798     DOI: 10.1067/mpd.2001.114480

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

1.  Trial of erythropoietin treatment in a boy with glutathione synthetase deficiency.

Authors:  J Sykut-Cegielska; A Jurecka; J Taybert; W Gradowska; M Pajdowska; E Pronicka
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Genotype, enzyme activity, glutathione level, and clinical phenotype in patients with glutathione synthetase deficiency.

Authors:  Runa Njålsson; Ellinor Ristoff; Katarina Carlsson; Andreas Winkler; Agne Larsson; Svante Norgren
Journal:  Hum Genet       Date:  2005-02-17       Impact factor: 4.132

3.  Acute administration of 5-oxoproline induces oxidative damage to lipids and proteins and impairs antioxidant defenses in cerebral cortex and cerebellum of young rats.

Authors:  Carolina Didonet Pederzolli; Caroline Paula Mescka; Bernardo Remuzzi Zandoná; Daniella de Moura Coelho; Angela Malysz Sgaravatti; Mirian Bonaldi Sgarbi; Angela Terezinha de Souza Wyse; Clóvis Milton Duval Wannmacher; Moacir Wajner; Carmen Regla Vargas; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2010-04-30       Impact factor: 3.584

4.  5-Oxoproline reduces non-enzymatic antioxidant defenses in vitro in rat brain.

Authors:  Carolina D Pederzolli; Angela M Sgaravatti; César A Braum; Cristina C Prestes; Giovanni K Zorzi; Mirian B Sgarbi; Angela T S Wyse; Clóvis M D Wannmacher; Moacir Wajner; Carlos S Dutra-Filho
Journal:  Metab Brain Dis       Date:  2007-01-20       Impact factor: 3.584

Review 5.  Protecting the mitochondrial powerhouse.

Authors:  Morten Scheibye-Knudsen; Evandro F Fang; Deborah L Croteau; David M Wilson; Vilhelm A Bohr
Journal:  Trends Cell Biol       Date:  2014-12-11       Impact factor: 20.808

Review 6.  Oxidative stress in inborn errors of metabolism: lessons from glutathione deficiency.

Authors:  E Ristoff; A Larsson
Journal:  J Inherit Metab Dis       Date:  2002-05       Impact factor: 4.982

7.  Human hereditary glutathione synthetase deficiency: kinetic properties of mutant enzymes.

Authors:  Runa Njålsson; Katarina Carlsson; Vikas Bhansali; Jia-Li Luo; Lennart Nilsson; Rudolf Ladenstein; Mary Anderson; Agne Larsson; Svante Norgren
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

8.  Alternative RNA splicing in expression of the glutathione synthetase gene in human cells.

Authors:  Marie Uchida; Maki Sugaya; Taichi Kanamaru; Hisashi Hisatomi
Journal:  Mol Biol Rep       Date:  2009-08-12       Impact factor: 2.316

9.  Glutathione synthetase deficiency: is gamma-glutamylcysteine accumulation a way to cope with oxidative stress in cells with insufficient levels of glutathione?

Authors:  E Ristoff; C Hebert; R Njålsson; S Norgren; O Rooyackers; A Larsson
Journal:  J Inherit Metab Dis       Date:  2002-11       Impact factor: 4.982

Review 10.  Drug treatment of inborn errors of metabolism: a systematic review.

Authors:  Majid Alfadhel; Khalid Al-Thihli; Hiba Moubayed; Wafaa Eyaid; Majed Al-Jeraisy
Journal:  Arch Dis Child       Date:  2013-03-26       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.